Cash and Cash Equivalents, at Carrying Value of PharmaCyte Biotech, Inc. from 30 Apr 2010 to 31 Jan 2026

Taxonomy & unit
us-gaap: USD
Description
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Summary
PharmaCyte Biotech, Inc. quarterly Cash and Cash Equivalents, at Carrying Value in USD history and change rate from 30 Apr 2010 to 31 Jan 2026.
  • PharmaCyte Biotech, Inc. Cash and Cash Equivalents, at Carrying Value for the quarter ending 31 Jan 2026 was $20,165,535, a 23% increase year-over-year.
Source SEC data
View on sec.gov
Cash and Cash Equivalents, at Carrying Value, Quarterly (USD)
Cash and Cash Equivalents, at Carrying Value, YoY Quarterly Change (%)

PharmaCyte Biotech, Inc. Quarterly Cash and Cash Equivalents, at Carrying Value (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $20,165,535 +$3,782,075 +23% 31 Jan 2026 10-Q 17 Mar 2026 2026 Q3
Q3 2025 $15,406,017 -$5,434,039 -26% 31 Oct 2025 10-Q 18 Dec 2025 2026 Q2
Q2 2025 $13,178,305 -$19,456,787 -60% 31 Jul 2025 10-Q 15 Sep 2025 2026 Q1
Q1 2025 $15,172,163 -$35,007,805 -70% 30 Apr 2025 10-Q 17 Mar 2026 2026 Q3
Q4 2024 $16,383,460 -$44,826,868 -73% 31 Jan 2025 10-Q 17 Mar 2025 2025 Q3
Q3 2024 $20,840,056 -$52,585,213 -72% 31 Oct 2024 10-Q 13 Dec 2024 2025 Q2
Q2 2024 $32,635,092 -$42,027,435 -56% 31 Jul 2024 10-Q 17 Sep 2024 2025 Q1
Q1 2024 $50,179,968 -$17,859,968 -26% 30 Apr 2024 10-K 11 Aug 2025 2025 FY
Q4 2023 $61,210,328 31 Jan 2024 10-Q 18 Mar 2024 2024 Q3
Q3 2023 $73,425,269 31 Oct 2023 10-Q 15 Dec 2023 2024 Q2
Q2 2023 $74,662,527 31 Jul 2023 10-Q 18 Sep 2023 2024 Q1
Q1 2023 $68,039,936 -$17,360,720 -20% 30 Apr 2023 10-K 13 Aug 2024 2024 FY
Q1 2022 $85,400,656 30 Apr 2022 10-K 31 Jul 2023 2023 FY
Q4 2014 $958,816 +$93,921 +11% 31 Jan 2015 10-Q 13 Mar 2015 2015 Q3
Q3 2014 $1,155,005 +$758,411 +191% 31 Oct 2014 10-Q 15 Dec 2014 2015 Q2
Q1 2014 $3,616,470 +$3,417,167 +1715% 30 Apr 2014 10-Q 13 Mar 2015 2015 Q3
Q4 2013 $864,895 +$831,561 +2495% 31 Jan 2014 10-Q 13 Mar 2015 2015 Q3
Q3 2013 $396,594 +$373,898 +1647% 31 Oct 2013 10-Q 15 Dec 2014 2015 Q2
Q2 2013 $206,038 +$181,696 +746% 31 Jul 2013 10-Q 16 Sep 2013 2014 Q1
Q1 2013 $199,303 +$183,580 +1168% 30 Apr 2013 10-Q 13 Mar 2015 2015 Q3
Q4 2012 $33,334 -$5,743 -15% 31 Jan 2013 10-Q 26 Mar 2013 2013 Q3
Q3 2012 $22,696 +$8,190 +56% 31 Oct 2012 10-Q 26 Dec 2012 2013 Q2
Q2 2012 $24,342 -$58,732 -71% 31 Jul 2012 10-Q 16 Sep 2013 2014 Q1
Q1 2012 $15,723 -$41,478 -73% 30 Apr 2012 10-Q 16 Sep 2013 2014 Q1
Q4 2011 $39,077 +$35,463 +981% 31 Jan 2012 10-Q 26 Mar 2013 2013 Q3
Q3 2011 $14,506 +$14,506 31 Oct 2011 10-Q 26 Dec 2012 2013 Q2
Q2 2011 $83,074 +$82,527 31 Jul 2011 10-Q 19 Sep 2012 2013 Q1
Q1 2011 $57,201 +$56,485 30 Apr 2011 10-K 29 Jul 2013 2013 FY
Q4 2010 $3,614 31 Jan 2011 10-Q 21 Mar 2012 2012 Q3
Q3 2010 $0 31 Oct 2010 10-Q 15 Dec 2011 2012 Q2
Q2 2010 $547* 31 Jul 2010 10-Q/A 20 Sep 2011 2012 Q1
Q1 2010 $716* 30 Apr 2010 10-K 14 Aug 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.